Literature DB >> 12925972

Mutational analysis of the LMO4 gene, encoding a BRCA1-interacting protein, in breast carcinomas.

Kate D Sutherland1, Jane E Visvader, David Y H Choong, Eleanor Y M Sum, Geoffrey J Lindeman, Ian G Campbell.   

Abstract

The LIM domain-only genes LMO1 and LMO2 are translocated in acute T cell leukemia (T-ALL) and have been shown to be oncogenes in T lymphoid cells. LMO4, the fourth member of this family, is overexpressed in more than 50% of sporadic breast cancers, suggesting a role in breast oncogenesis. We recently found that LMO4 interacts with the breast/ovarian tumor suppressor BRCA1 and that LMO4 can repress its transcriptional activity. Since proto-oncogene deregulation can result from activating mutations in their coding or regulatory sequences, we explored whether the LMO4 gene undergoes somatic mutagenesis in breast cancer. Mutation analysis of the coding and 3' untranslated regions of the LMO4 gene was performed on 82 primary breast and 22 tumor cell lines. A somatic mutation was detected in one primary breast cancer, at the 3' end of exon 2, but was not present in normal DNA derived from the same patient. This mutation causes a frame-shift and potentially results in a truncated LMO4 polypeptide, LIM1(mut), lacking the second LIM domain. This mutant protein could still bind Ldb1 but no longer associated with CtIP or BRCA1. Our results show that somatic mutations within the LMO4 gene do occur in breast cancer but at a very low frequency. Thus, the primary mechanism by which LMO4 is deregulated in breast cancers appears to reflect overexpression of the gene rather than the acquisition of activating genetic mutations. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12925972     DOI: 10.1002/ijc.11343

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Repression of Lim only protein 4-activated transcription inhibits proliferation and induces apoptosis of normal mammary epithelial cells and breast cancer cells.

Authors:  Yingpu Tian; Ning Wang; Zhongxian Lu
Journal:  Clin Exp Metastasis       Date:  2010-06-06       Impact factor: 5.150

2.  Genomic analysis of cancer tissue reveals that somatic mutations commonly occur in a specific motif.

Authors:  Nick M Makridakis; Lúcio Fábio Caldas Ferraz; Juergen K V Reichardt
Journal:  Hum Mutat       Date:  2009-01       Impact factor: 4.878

3.  Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer.

Authors:  Aaron G Lewis; James Flanagan; Anna Marsh; Gulietta M Pupo; Graham Mann; Amanda B Spurdle; Geoffrey J Lindeman; Jane E Visvader; Melissa A Brown; Georgia Chenevix-Trench
Journal:  Breast Cancer Res       Date:  2005-10-21       Impact factor: 6.466

4.  Prognostic value of CtIP/RBBP8 expression in breast cancer.

Authors:  Isabel Soria-Bretones; Carmen Sáez; Manuel Ruíz-Borrego; Miguel A Japón; Pablo Huertas
Journal:  Cancer Med       Date:  2013-10-03       Impact factor: 4.452

5.  The structure of an LIM-only protein 4 (LMO4) and Deformed epidermal autoregulatory factor-1 (DEAF1) complex reveals a common mode of binding to LMO4.

Authors:  Soumya Joseph; Ann H Kwan; Philippa H Stokes; Joel P Mackay; Liza Cubeddu; Jacqueline M Matthews
Journal:  PLoS One       Date:  2014-10-13       Impact factor: 3.240

6.  LHX1 as a potential biomarker regulates EMT induction and cellular behaviors in uterine corpus endometrial carcinoma.

Authors:  Ye Tian; Fang Wen; Shuo Wang; Na Lv
Journal:  Clinics (Sao Paulo)       Date:  2022-09-15       Impact factor: 2.898

7.  LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression.

Authors:  M E Montañez-Wiscovich; D D Seachrist; M D Landis; J Visvader; B Andersen; R A Keri
Journal:  Oncogene       Date:  2009-08-03       Impact factor: 9.867

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.